Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or peripheral (PAD). We explored whether CHA2DS2-VASc or CHADS2 scores, well-validated tools assessing risk of thromboembolic atrial fibrillation, can ...

background: considering the existence of controversies about the predictive value of inflammatory markers for cardiovascular disease (cvd), we aimed to compare the level of high?sensitivity c?reactive protein (hs?crp) and interlukin?6 (il?6) level in chronic hemodialysis (hd) patients with and without cvd. materials and methods: in this historical cohort study, hd patients with and without cvd ...

BACKGROUND It is desirable that those at highest risk of cardiovascular disease should have priority for preventive measures, eg. treatment with prescription drugs to modify their risk. We wanted to investigate to what extent present use of cardiovascular medication (CVM) correlates with cardiovascular risk estimated by three different risk scores (Framingham, SCORE and NORRISK) ten years ago. ...

BACKGROUND The aim of the study is to develop risk scores with traditional factors for all-cause and cardiovascular mortality among coronary heart disease (CHD) patients. METHODS AND RESULTS We performed a prospective cohort study of 1911 CHD patients aged 40 and older. Cox models were used to estimate the association of traditional factors [sex, age, fasting blood glucose (FBG), high-density...

Coronary risk in patients with type 2 diabetes mellitus can be calculated using population-based scores or diabetes-specific scores. Our objective was to compare the results with both scores in a group of patients with type 2 diabetes and no history of cardiovascular disease. We analyzed the results for 101 patients aged 40 to 65 years with type 2 diabetes and no prior cardiovascular disease. T...